Nanoparticulate drug delivery systems for cancer chemotherapy

Molecular Membrane Biology

Volumn 27, Issue 7, 2010, Pages 215-231

  Saha, Ranendra N ^a   Vasanthakumar, Sekar ^a   Bende, Girish ^a   Snehalatha, Movva ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

brain targeting; cytotoxicity; intracellular trafficking; opsonization; Polymeric lipid nanoparticles

Indexed keywords

ASPARAGINASE MACROGOL; CYCLOSPORIN A; DAUNORUBICIN; DIOLEOYLPHOSPHATIDYLETHANOLAMINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; IMATINIB; INDOMETACIN; LEUCINE ENKEPHALIN[2 DEXTRO ALANINE 6 ARGININE]; LIPOSOME; LOPERAMIDE; MACROGOL; NANOCAPSULE; NANOPARTICLE; NANOSPHERE; PACLITAXEL; POLY(ETHYL 2 CYANOACRYLATE); POLYGLACTIN; POLYSORBATE 20; POLYSORBATE 40; POLYSORBATE 60; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; TENIPOSIDE; TUBOCURARINE CHLORIDE; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; AREA UNDER THE CURVE; BIOCOMPATIBILITY; BLOOD BRAIN BARRIER; BONE; BREAST CANCER; CANCER CHEMOTHERAPY; CELL NUCLEUS; CELL TRANSPORT; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG RETENTION; DRUG TRANSPORT; EMULSION; ENCAPSULATION; ENDOPLASMIC RETICULUM; ENDOSOME; EYE; GELATION; HUMAN; KAPOSI SARCOMA; LUNG; LYSOSOME; MAXIMUM PLASMA CONCENTRATION; MICELLE; MITOCHONDRION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; OVARY CANCER; PARTICLE SIZE; PERMEABILITY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; STRATUM CORNEUM; SURFACE PROPERTY; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; DOSAGE FORMS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MICE; NANOPARTICLES; NEOPLASMS; PARTICLE SIZE; POLYMERS; RABBITS; RATS; TISSUE DISTRIBUTION;

EID: 78049336287     PISSN: 09687688     EISSN: 14645203     Source Type: Journal    
DOI: 10.3109/09687688.2010.510804     Document Type: Review

References (88)

1. Allenmann E, Leroux JC, Gurny R, Doelker E. 1993. In vitro extended-release properties of drug-loaded poly (DL-lactic acid) NPs produced by a salting-out procedure. Pharm Res 10:1732-1737.
2. Amidi M, Romeijn SG, Borchard G, Junginger HE, Hennink WE, Jiskoot W. 2006. Preparation and characterization of protein-loaded N-trimethyl Chitosan nanoparticles as nasal delivery system. J Control Rel 111:107-116.
3. Aston R, Siebert RS, Canham L, Ogden J. 2005. Nanotechnology application for drug delivery. Pharmaceut Technol Eur 17: 21-28.
4. Bilati U, Allemann E, Doelker E. 2005. Nanoprecipitation versus emulsion-based techniques for the encapsulation of proteins into biodegradable nanoparticles and process-related stability issues. AAPS PharmSciTech 6:E594-604.
5. Borgia SL, Regehly M, Sivaramakrishnan R, Mehnert W, Korting HC, Danker K, Röder B, Kramer KD, Korting MS. 2005. Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy. J Control Rel 110:151-163.
6. Breunig M, Bauer S, Goepferich A. 2008. Polymer and nanopar-ticles: Intelligent tools for intracellular targeting? Eur J. Pharm Biopharm 68:112-128.
7. Brigger I, Dubernet C, Couvreur P. 2002. Nanoparticles in cancer therapy and diagnosis. Adv Drug Del Rev 54:631-651.
8. Champion JA, Katare YK, Mitragotri S. 2007. Particle shape: A new design parameter for micro and nanoscale drug delivery carriers. J Control Rel 121:3-9.
9. Couvreur P, Kante B, Roland M, Guiot P, Bauduin P. Speiser P. 1979. Polycyanoacrylate nanocapsules as potential lysosomatropic carriers: Preparation, morphological and sorp-tive properties. J Pharm Pharmacol 31:331-332.
10. Couvreur P, Vauthier C. 2006. Nanotechnology: Intelligent design to treat complex disease. Pharm Res 23:1417-1450.
11. Cummings J, Allan L, Smyth J. 1994. Encapsulation of mitomycin C in albumin microspheres markedly alters pharmacokinetics, drug quinine reduction in tumor tissue and antitumor activity. Biochem Pharmacol 47:1345-1356.
12. Daemen T, Hofstede G, Kate MTT, Woudenberg IAJMB, Scherphof G. 1995. Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic activity of liver macro-phages. Int J Cancer 61:716-721.
13. Dass CR. 2002. Biochemical and biophysical characteristics of lipoplexes pertinent to solid tumor gene therapy. Int J Pharm 241:1-25.
14. De Campos AM, Sanchez A, Alonso MJ. 2001. Chitosan nano-particles: A new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A. Int J Pharm 224:159-168.
15. Derakhshandeh K, Erfan M, Dadashzadeh S. 2007. Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics. Eur J Pharm Biopharm 66:34-41.
16. Desgouilles S, Vauthier C, Bazile D, Vacus J, Grossiord L, Veillard M, Couvreur P. 2003. The design of nanoparticles obtained by solvent evaporation: A comprehensive study. Lang-muir 19:9504-9510.
17. Dillen K, Vandervoort J, Mooter GV, Ludwig A. 2006. Evaluation of ciprofloxacin-loaded Eudragit RS 100 or Rl 100/PLGA nanoparticles. Int J Pharm 314:72-82.
18. Discher DE, Eisenberg A. 2002. Material science: soft surface: polymer vesicles. Science 297:967-973.
19. Duncan R. 2006. Polymer conjugates as anticancer nanomedicines. Nat Rev Cancer 6:688-701.
20. Fahmy TM, Fong PM, Park J, Constable T, Saltzman WM. 2007. Nanosystems for simultaneous imaging and drug delivery to T cells. AAPS J 9(2):E171-180.
21. Florence AT, Hussain N. 2001. Trancytosis of nanoparticles and dendrimers delivery system: Evolving vistar. Adv Drug Deliv Rev 50:S69-89.
22. Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, Rong Z, Chen H, Jiang X. 2007. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release 121:156-167.
23. Gaur U, Sahoo SK. 2000. Biodistribution of fluoresceinated dex-tran using novel nanoparticles evading reticuloendothelial system. Int J Pharm 202:1-10.
24. Gill S, Lobenberg R, Ku T, Azarmi S, Roa W, Prenner EJ. 2007. Nanoparticles: Characteristics, mechanisms of action, and tox-icity in pulmonary drug delivery-a review. J Biomed Nano-technol 3:107-119.
25. Girish B, Kollipara S, Kolachina V, Saha R. 2007. Development and validation of a stability indicating RP-LC method for determination of Imatinib Mesylate. Chromatographia 66:859-866.
26. Graham ML. 2003. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 55:1293-1302.
27. Grau MJ, Kayser O, Muller RH. 2000. Nanosuspension of poorly soluble drugs-reproducibility of small scale production. Int J Pharm 196:155-157.
28. Gref R, Minamitake Y, Peracchia MT, Domb A, Trubetskoy V, Torchilin V, Langer R. 1997. Biodegradable long-circulating polymeric nanospheres. Science 263:1600-1603.
29. Harris JM, Chess RB. 2003. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2:214-221.
30. Hasani S, Pellequer Y, Lamprechi A. 2009. Selective adhesion of nanoparticles to inflamed tissue in gastric ulcers. Pharm Res 26 (5):1149-1154.
31. Hashizume H, Baluk P, Morikawa S, McLean JW, Thurston G, Roberge S, Jain RK, McDonald DM. 2000. Opening between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 156:1363-1380.
32. Hassan AS, Sapin A, Lamprecht A, Emond E, Ghazouani El, Maincent P. 2009. Composite microparticles with in vivo reduction of the burst release effect. Eur J Pharm Biopharm 73: 337-344.
33. Kemken J, Ziegler A, Muller BW. 1992. Influence of supersatura-tion on the pharmacodynamic effect of bupranolol after dermal administration using microemulsion as vehicle. Pharm Res 9:554-558.
34. Kim SE, Durairaj C, Kadam RS, Lee SJ, Mo Y, Geroski DH, Kompella UB, Edelhauser HF. 2009. Human scleral diffusion of anticancer drugs from solution and nanoparticle formulation. Pharm Res 26(5):1155-1161.
35. Kisel MA, Perez-soler R, Cruz ME. 2001. Liposomes with phos-phatidylethanol as a carrier for oral delivery of insulin: Studies in the rat. Int J Pharm 216:105-114.
36. Klaus Z, Julia K, Ernst W, Conrad C. 2004. Gelatin nanoparticles as a new and simple gene delivery system. J Pharm Pharmaceut Sci 7(4):22-28.
37. Kollipara S, Girish B, Snehalatha M, Saha RN. 2010. Application of rotatable central composite design in the preparation and optimization of poly (lactic-co-glycolic acid) nanoparticles for controlled delivery of paclitaxel. Drug Dev Ind Pharm (Posted online on June 14, 2010, doi: 10.3109103639045.2010. 487263).
38. Korting MS, Mehnert W, Korting HS. 2007. Lipid nanoparticles for improved topical application of drug for skin diseases. Adv Drug Deliv Rev 59:427-443.
39. Kreuter J. 2001. Nanoparticulate system for brain delivery of drug. Adv Drug Deliv Rev 47:65-81.
40. Lamprecht A, Schafer U, Lehr CM. 2001. Size dependent targeting of micro-and nanoparticles carriers to the inflamed colonic mucosa. Pharm Res 18:788-793.
41. Langer R. 1998. Drug delivery and targeting. Nature 392:5-10.
42. Letchford K, Burt H. 2007. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structure: Micelles, nanospheres, nanocapsules and polymersomes. Eur J Pharm Biopharm 65:259-269.
43. Links M, Brown R. 1999. Clinical relevance of the molecular mechanisms of resistance to anti-cancer drugs. Expert Rev Anticancer Ther 1999:1-21.
44. Maeda H, Sawa T, Konno T. 2001. Mechanism of tumor-targeted delivery of macromolecular drug including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release 74:47-61.
45. Maeda H, Bharate GY, Daruwalla J. 2009. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 71:409-419.
46. Mainardes RM, Evangelista RC. 2005. PLGA nanoparticles containing praziquantel: Effect of formulation variables on size distribution. Int J Pharm 290:137-144.
47. Matsumoto K, Yamamoto T, Kamata R, Marda H. 1984. Patho-genesis of serratial infection: Activation of the Hageman facto-perkallikerin cascade by serratial protease. J Biochem 96: 739-749.
48. Medina C, Santos-Martinez MJ, Radomski A, Corrigan OI, Radomski MW. 2007. Nanoparticles: Pharmacological and toxicological significance. Br J Pharmacol 150:552-558.
49. Miller NS, Johnston TP. 2005. Current strategies used to enhance the paracellular transport of therapeutic polypeptides across the intestinal epithelium. Int J Pharm 294:201-216.
50. Miklos GL. 2005. The human cancer genome project-one more misstep in the war on cancer. Nat Biotechnol 23: 535-537.
51. Miyazaki S, Takahashi A, Kubo W. 2003. Poly n-butyl cyanoac-rylate (PNBCA) nanocapsules as a carrier for NSAIDs: In vitro release and in vivo skin penetration. J Pharm Pharmaceut Sci 6 (2):240-245.
52. Moghimi SM, Hunter AC, Murray JC. 2001. Long-circulating and target-specific nanoparticles: Theory to practice. Pharmacol Rev 53:283-218.
53. Mu L, Feng SS. 2003. PLGA/TPGS nanoparticles for controlled release of paclitaxel: Effect of the emulsion and drug loading ratio. Pharm Res 20:1864-1872.
54. Muller RH, Radtka M, Wilsing SA. 2002. Solid lipid nano-particles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatolodical preparation. Adv Drug Deliv Rev 1:S131-155.
55. Nguyen CA, Kouakou YNK, Allemann E, Doelker E, Guerrero DQ, Fessi H, Gurny R. 2006. Preparation of surfactant-free nanoparticles of methacrylic acid copolymer used for film coating. AAPS PharmSciTech 7:E1-7.
56. Osborne DW, Ward AJ, Neil KJ. 1991. Microemulsions as topical delivery vehicles: In-vitro transdermal studies of a model hydro-philic drug. J Pharm Pharmacol 43:450-454.
57. Otsuka H, Nagasaki Y, Kataoka K. 2003. PEGylated nanoparticles or biological and pharmaceutical applications. Adv Drug Deliv Rev 55:403-419.
58. Owens De III, Peppas NA. 2006. Opsonization, biodistribution and pharmacokinetics of polymer nanoparticles. Int J Pharm 307:93-102.
59. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. 2002. Rapid endo-lysosomal escape of poly (D, L-lactide-co-glyco-lide) nanoparticles: Implications for drug and gene delivery. FASEB J 16:1217-1226.
60. Panyam J, Labhasetwar V. 2003a. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347.
61. Panyam J, Labhasetwar V. 2003b. Dynamics of endocytosis and exocytosis of poly (D, L-lactide-co-glycolide) nano-particles in vascular smooth muscle cells. Pharm Res 20: 110-118.
62. Pople PV, Singh KK. 2006. Development and evaluation of topical formulation containing solid lipid nanoparticles of vitamin A. AAPS PharmSciTech 7(4):E1-7.
63. Saez A, Guzman M, Molpeceres J, Aberturas MR. 2000. Freeze-drying of polycaprolactone and poly (D,L-lactic-glycolic) nano-particles induce minor particle size changes affecting the oral pharmacokinetic of loaded drugs. Eur J Pharm Biopharm 50:379-387.
64. Salamanca AE, Diebold Y, Calonge M, Vazquez CG, Callejo S, Vila A, Aloso MJ. 2006. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: Toxicity, uptake mechanism and in vivo tolerance. Invest. Ophthalmol Vis Sci 47 (4):1416-1425.
65. Sekar V, Selladurai ST, Saha RN. 2009. A new, simple HPLC method for estimation of paclitaxel in micro-volume rat plasma. AAPS J 11(S2):1953.
66. Serpe L, Catalano MG, Cavalli R, Ugazio E, Bosco O, Canaparo R, Muntoni E, Frairia R, Gasco MR, Eandi M, Zara GP. 2004. Cytotoxicity of anticancer drug incorporated in solid lipid nanoparticles on HT-29 colorectal cancer cell line. Eur J Pharm Biopharm 58:673-680.
67. Shabbits JA, Krishna R, Mayer LD. 2001. Molecular and pharmacological strategies to overcome multidrug resistance. Expert Rev Anticancer Ther 1:585-594.
68. Sinjan De, Miller DW, Robinson DH. 2005. Effect of particle size of nanospheres and microspheres on the cellular-association and cytotoxicity of paclitaxel in 4T1 cells. Pharm Res 22:766-775.
69. Skipper H, Schabel J, Wilcox W. 1964. Experimental evaluation of potential anticancer agents XIII: On the criteria and kinetics associated with 'curability' of experimental leukemia. Cancer Treat Rep 55:1-111.
70. Snehalatha M, Venugopal K, Saha RN, Babbar AK, Sharma RK. 2008a. EP loaded PLGA and PCL nanoparticles II: Biodistribution and pharmacokinetic after radiolabeling with Tc-99m. Drug Deliv 15:277-287.
71. Snehalatha M, Venugopal K, Saha RN. 2008b. Etoposide-loaded PLGA and PCL nanoparticles I: Preparation and effect of formulation variables. Drug Deliv 15:267-275.
72. Stephanie EAG, Patrick DP, Jin L, Ji G, Moo JC, De Simone JM. 2007. Nanofabricated particles for engineered drug therapies: A preliminary biodistribution study of PRINT nanoparticles. J Control Release 121:10-18.
73. Stewart BW, Kleihues P. 2003. World cancer report-International agency for research on cancer (IARC), Non-serial publication. Geneva: World Health Organization.
74. Stolnik S, Dunn SE, Garnett MC, Davies MC, Coombes AG, Taylor DC, Irving MP, Purkiss SC, Tadros TF, Davis SS. 1994. Surface modification of poly (lactide-co-glycolide) nanospheres by biodegradable poly (lactide)-poly (ethylene glycol) copoly-mers. Pharm Res 11:1800-1808.
75. Thanou M, Verhoef JC, Junginger HE. 2001. Chitosan and its derivatives as intestinal absorption enhancers. Adv Drug Deliv Rev 50:S91-101.
76. Torchilin V. 2007. Targeted pharmaceutical nanocarriers for cancer theraphy and imaging. AAPS J 9(2):E128-147.
77. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, Tacchi R, Bertolini A, Vandelli MA, Forni F. 2007. Targeting the central nervous system: In vivo experiment with peptide-derivatized nanoparticles loaded with Loperamide and Rhoda-mine-123. J Control Release 122:1-9.
78. Trotta M. 1999. Influence of phase transformation on indo-methacin release from microemulsion. J Control Rel 60: 399-405.
79. Tsinontides SC, Rajniak P, Hunke WA, Placek J, Reynolds SD. 2004. Freeze drying-principle and practice for successful scale-up to manufacturing. Int J Pharm 280:1-16.
80. Vauthier C, Labarre D, Ponchel G. 2007. Design aspects of poly (alkylcyanoacrylate) nanoparticles for drug delivery. J Drug Targeting 15:641-663.
81. Vauthier C, Bouchemal K. 2008. Method for the preparation and manufacture of polymeric nanoparticles. Pharm Res 26: 1025-1058.
82. Vauthier C, Cabane B, Labarre D. 2008. How to concentrate nanoparticles and avoid aggregation? Eur J Pharm Biopharm 69:466-475.
83. Vyas SP, Khar RK. 2001. Targeted and controlled drug delivery. New Delhi, India: CBS Publisher and Distributor.
84. Wilson B, Samanta MK, Santhi K, Sampath KKP, Paramakrishnan N, Suresh B. 2008. Targeted delivery of tacrine into the brain with polysorbates 80-coated poly (n-butylcyanoa-crylate) nanoparticles. Eur J Pharm Biopharm 70:75-84.
85. Xiong R, Lu W, Yue P, Xu R, Li J, Chen T, Wang P. 2008. Distribution of an i.v. injectable nimodipine nanosuspension in mice. J Pharm Pharmacol 60:1155-1159.
86. Yang W, Peters JI, Williams RO III. 2008. Inhaled nanoparticles-a current review. Int J Pharm 356:239-247.
87. Yuan F, Dellian M, Fukumuar D, Leunig M, Berk DA, Torchilin VP, Jain RK. 1995. Vascular permeability in a human tumor xenograft: Molecular size dependence and cutoff size. Cancer Res 55:3752-3756.
88. Zili Z, Sfar S, Fessi H. 2005. Preparation and characterization of poly-caprolactone nanoparticles containing griseofulvin. Int J Pharm 294:261-267.